InvaGen in agreement with Avenue Therapeutics for specialty hospital business in the US
Upon first stage closing, InvaGen Pharmaceuticals, a Cipla subsidiary, to acquire shares representing a 33.3 per cent stake in…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Home » Latest Updates » Page 115
Browsing Category
Latest Updates
DRL’s Duvvada unit undergoes German regulator’s follow-on-audit
The facility is considered compliant and the EU-GMP certification continues to remain active with one specific exclusion of a new…
Flexible biopatch can deliver precise drug dosage
Researchers hope to develop the patch's functionality to act as an external skin patch, lowering the pain, invasiveness and…
Zydus Cadila gets US FDA nod for anti-fungal ointment
The drug will be manufactured at the group's Topical manufacturing facility at Ahmedabad
Cipla receives final approval for generic version of Roche’s Valcyte
The drug is indicated for use in the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome and prevention…
Wockhardt Q2 net loss widens to ₹ 23 crore
The company, which plans to raise up to ₹ 1,800 crore through private placement of non-convertible debentures, had reported a…
Novartis division Sandoz recalls one lot of blood pressure drug
The drug is made by China’s Zhejiang Huahai Pharmaceutical
Mylan and Theravance’s COPD treatment gets FDA approval
The treatment, Yupelri, is a once-daily inhalable solution to be used by patients of COPD
Glenmark to launch trial in solid tumours for its CD38xCD3 bispecific antibody GBR 1342
GBR 1342 is one of three investigational immuno-oncology agents based on Glenmark’s proprietary BEAT platform
Strides’ subsidiary inks pact with SUDA Pharmaceuticals for migraine drug
Under the terms of agreement, SUDA will receive an upfront cash payment of $ 0.4 million and a further payment of $ 0.6 million on…